T21 screening – NIPT – Pre-eclampsia – Fœtal biochemistry – Eurofins Biomnis

Great progress has been made in screening for trisomy 21 (T21), a sector closely regulated in France since 1997, with a maternal serum marker (MSM) screening rate of around 80%. The benefits of NIPS (Non-Invasive Prenatal Screening) have been demonstrated, especially for women with an increased risk of trisomy 21 according to MSM (without warning signs on ultrasound).

Also related to pregnancy, further pathophysiological research on pre-eclampsia (PE) has led to the development of angiogenic and antiangiogenic factor analyses that can be used for predictive and screening tests.

More information

Mettez à jour votre navigateur pour consulter ce site

Mettez à jour votre navigateur pour consulter ce site